ARTICLE | Clinical News
pSivida submits MAA to EMA for Durasert
July 13, 2017 11:57 PM UTC
pSivida Corp. (NASDAQ:PSDV; ASX:PVA) submitted an MAA to EMA for Durasert to treat posterior segment uveitis. The company says it is in discussions to out-license the 3-year sustained-release fluocino...
BCIQ Company Profiles